Overview

A Study of LY3209590 as a Weekly Basal Insulin Compared to Insulin Glargine in Adult Participants With Type 2 Diabetes on Multiple Daily Injections

Status:
Not yet recruiting

Trial end date:
2023-10-17

Target enrollment:

Participant gender:

Summary

The main purpose of this study is to evaluate the efficacy and safety of once-weekly LY3209590 compared with daily insulin glargine in participants with type 2 diabetes (T2D).

Phase:

Phase 3

Details

Lead Sponsor:

Eli Lilly and Company

Treatments:

Insulin
Insulin Glargine
Insulin Lispro
Insulin, Globin Zinc